Strattera: Uses, Forms and Safety Reference

Strattera contains atomoxetine and is used within an ADHD treatment plan. Unlike a capsule that permits sprinkling, this product must be swallowed intact; cardiovascular assessment and monitoring for mood changes also matter.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) atomoxetine hydrochloride (strengths expressed as atomoxetine)
Medicine class Selective norepinephrine reuptake inhibitor
Forms and strengths Oral capsules: 10, 18, 25, 40, 60, 80 and 100 mg

Atomoxetine within a broader ADHD plan

Strattera is labeled in the United States for ADHD in adults and pediatric patients aged 6 years and older. It is intended as part of a total treatment program that may include educational, psychological and social measures. It is not a general treatment for every cause of poor concentration.

Source: [1]

Swallow the capsule intact

The seven capsule strengths range from 10 to 100 mg of atomoxetine. Capsules should not be opened because their contents can irritate the eyes. The prescription may use once-daily or divided administration. Age, weight, liver function and interacting medicines affect prescribing; the strength list is not a dose calculator.

Source: [1]

The pediatric boxed warning

The label warns of increased suicidal thoughts and behaviors in pediatric patients. Close observation for clinical worsening or unusual behavioral changes is needed, particularly early in treatment and when the dose changes. Tell the prescribing team promptly about concerning symptoms and seek emergency help for immediate danger.

Source: [1]

Cardiovascular and liver precautions

Blood pressure and pulse require monitoring. Severe cardiovascular disorders, narrow-angle glaucoma and pheochromocytoma are among the contraindications. The label also warns about severe liver injury: jaundice or other signs of liver trouble need prompt assessment. Growth should be followed in children receiving treatment.

Source: [1]

Interactions can alter atomoxetine exposure

Strong CYP2D6 inhibitors can raise atomoxetine exposure and change the prescribing approach. MAO inhibitors are contraindicated within the label's separation interval. Bring prescription drugs, nonprescription products and inhaled medicines to a medication review. Do not convert an ADHD comparison into a self-directed switch.

For related product context, see the QELBREE and Strattera comparison; treatment changes still require a prescribing review.

Source: [1]

Questions and answers

May Strattera be sprinkled onto food?

No. Strattera capsules should be swallowed intact and must not be opened.

Does atomoxetine require heart-rate checks?

Yes. The label calls for blood pressure and pulse checks before treatment, after increases and periodically.

What does the Strattera liver warning mean?

Severe liver injury has been reported. Yellow skin or eyes and other suspected liver symptoms require prompt medical assessment.

Related reading

Sources

  1. Strattera: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026